Advaxis
Princeton
About Advaxis
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $156.2M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2022)
- Ticker: nasdaq:ADXS
- Website: advaxis.com
- Phone: 609-452-9813
Industries & Categories
Biotechnology, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/advaxis-74539 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.